GlaxoSmithKline Ebit vs Research Development Analysis

GSK Stock

USD 33.96 0.26 0.77%

GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC ADR latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC ADR is a good investment. Please check the relationship between GlaxoSmithKline PLC Ebit and its Research Development accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC ADR Ebit account and Research Development. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between GlaxoSmithKline PLC's Ebit and Research Development is 0.43. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Research Development in the same time period over historical financial statements of GlaxoSmithKline PLC ADR, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Ebit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of GlaxoSmithKline PLC ADR are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Ebit i.e., GlaxoSmithKline PLC's Ebit and Research Development go up and down completely randomly.

Correlation Coefficient

0.43

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ebit

Research Development

Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although Enterprise Value Over EBITDA will most likely fall to 7.68.

	2021	2022	2023	2024 (projected)
Interest Expense	784M	879M	775M	502.2M
Depreciation And Amortization	2.1B	2.1B	2.3B	2.4B

Interest Expense Depreciation And Amortization

GlaxoSmithKline PLC fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets
Total Assets		0.92	0.22	0.89	0.5	0.89	0.9	0.33	0.61	0.99	0.04	0.59	0.22	0.29	-0.02	0.95	0.95	0.5	0.97	0.32	0.91	0.7	0.71	0.7	0.11	0.94
Short Long Term Debt Total	0.92		0.09	0.83	0.41	0.88	0.98	0.41	0.65	0.9	-0.08	0.55	0.02	0.28	-0.06	0.91	0.9	0.61	0.91	0.23	0.87	0.73	0.87	0.73	0.02	0.82
Other Current Liab	0.22	0.09		0.09	0.78	0.13	0.05	-0.62	0.19	0.17	0.57	0.55	0.78	0.27	0.37	0.05	0.16	-0.3	0.07	0.49	0.37	0.33	-0.2	0.33	0.68	0.13
Total Current Liabilities	0.89	0.83	0.09		0.3	0.89	0.83	0.53	0.45	0.87	0.14	0.53	0.16	0.29	0.1	0.83	0.94	0.54	0.94	0.36	0.87	0.71	0.72	0.71	-0.07	0.77
Total Stockholder Equity	0.5	0.41	0.78	0.3		0.27	0.43	-0.44	0.19	0.49	0.54	0.44	0.77	0.57	0.2	0.29	0.35	-0.26	0.31	0.56	0.48	0.33	0.25	0.33	0.88	0.51
Property Plant And Equipment Net	0.89	0.88	0.13	0.89	0.27		0.83	0.56	0.74	0.84	0.05	0.66	-0.02	0.33	-0.1	0.91	0.97	0.77	0.94	0.43	0.93	0.92	0.71	0.92	-0.2	0.73
Net Debt	0.9	0.98	0.05	0.83	0.43	0.83		0.38	0.5	0.89	-0.01	0.46	0.08	0.31	-0.01	0.87	0.87	0.54	0.89	0.24	0.82	0.65	0.9	0.65	0.07	0.82
Accounts Payable	0.33	0.41	-0.62	0.53	-0.44	0.56	0.38		0.33	0.33	-0.28	0.0	-0.61	0.11	-0.33	0.44	0.48	0.78	0.5	0.04	0.3	0.43	0.49	0.43	-0.71	0.3
Cash	0.61	0.65	0.19	0.45	0.19	0.74	0.5	0.33		0.56	-0.3	0.71	-0.24	0.03	-0.24	0.68	0.64	0.64	0.61	0.08	0.72	0.77	0.37	0.77	-0.19	0.48
Non Current Assets Total	0.99	0.9	0.17	0.87	0.49	0.84	0.89	0.33	0.56		0.0	0.5	0.22	0.26	-0.07	0.94	0.92	0.45	0.95	0.28	0.85	0.63	0.7	0.63	0.13	0.97
Non Currrent Assets Other	0.04	-0.08	0.57	0.14	0.54	0.05	-0.01	-0.28	-0.3	0.0		0.27	0.75	0.73	0.45	-0.08	0.08	-0.21	0.01	0.84	0.19	0.19	-0.04	0.19	0.49	-0.02
Cash And Short Term Investments	0.59	0.55	0.55	0.53	0.44	0.66	0.46	0.0	0.71	0.5	0.27		0.25	0.26	0.43	0.56	0.64	0.39	0.57	0.34	0.84	0.75	0.31	0.75	0.11	0.35
Common Stock Total Equity	0.22	0.02	0.78	0.16	0.77	-0.02	0.08	-0.61	-0.24	0.22	0.75	0.25		0.38	0.44	0.03	0.11	-0.52	0.08	0.57	0.2	0.01	-0.12	0.01	0.78	0.25
Common Stock Shares Outstanding	0.29	0.28	0.27	0.29	0.57	0.33	0.31	0.11	0.03	0.26	0.73	0.26	0.38		0.02	0.2	0.31	0.15	0.25	0.84	0.36	0.42	0.35	0.42	0.41	0.27
Short Term Investments	-0.02	-0.06	0.37	0.1	0.2	-0.1	-0.01	-0.33	-0.24	-0.07	0.45	0.43	0.44	0.02		-0.1	-0.03	-0.26	-0.02	0.02	0.17	-0.03	0.0	-0.03	0.24	-0.14
Non Current Liabilities Total	0.95	0.91	0.05	0.83	0.29	0.91	0.87	0.44	0.68	0.94	-0.08	0.56	0.03	0.2	-0.1		0.94	0.67	0.97	0.25	0.87	0.71	0.71	0.71	-0.13	0.88
Inventory	0.95	0.9	0.16	0.94	0.35	0.97	0.87	0.48	0.64	0.92	0.08	0.64	0.11	0.31	-0.03	0.94		0.66	0.98	0.4	0.94	0.82	0.7	0.82	-0.08	0.82
Other Stockholder Equity	0.5	0.61	-0.3	0.54	-0.26	0.77	0.54	0.78	0.64	0.45	-0.21	0.39	-0.52	0.15	-0.26	0.67	0.66		0.64	0.16	0.58	0.72	0.53	0.72	-0.66	0.35
Total Liab	0.97	0.91	0.07	0.94	0.31	0.94	0.89	0.5	0.61	0.95	0.01	0.57	0.08	0.25	-0.02	0.97	0.98	0.64		0.31	0.91	0.74	0.75	0.74	-0.11	0.88
Property Plant And Equipment Gross	0.32	0.23	0.49	0.36	0.56	0.43	0.24	0.04	0.08	0.28	0.84	0.34	0.57	0.84	0.02	0.25	0.4	0.16	0.31		0.43	0.54	0.18	0.54	0.32	0.26
Total Current Assets	0.91	0.87	0.37	0.87	0.48	0.93	0.82	0.3	0.72	0.85	0.19	0.84	0.2	0.36	0.17	0.87	0.94	0.58	0.91	0.43		0.88	0.65	0.88	0.05	0.72
Capital Stock	0.7	0.73	0.33	0.71	0.33	0.92	0.65	0.43	0.77	0.63	0.19	0.75	0.01	0.42	-0.03	0.71	0.82	0.72	0.74	0.54	0.88		0.55	1.0	-0.13	0.49
Short Term Debt	0.71	0.87	-0.2	0.72	0.25	0.71	0.9	0.49	0.37	0.7	-0.04	0.31	-0.12	0.35	0.0	0.71	0.7	0.53	0.75	0.18	0.65	0.55		0.55	-0.04	0.65
Common Stock	0.7	0.73	0.33	0.71	0.33	0.92	0.65	0.43	0.77	0.63	0.19	0.75	0.01	0.42	-0.03	0.71	0.82	0.72	0.74	0.54	0.88	1.0	0.55		-0.13	0.49
Retained Earnings	0.11	0.02	0.68	-0.07	0.88	-0.2	0.07	-0.71	-0.19	0.13	0.49	0.11	0.78	0.41	0.24	-0.13	-0.08	-0.66	-0.11	0.32	0.05	-0.13	-0.04	-0.13		0.2
Intangible Assets	0.94	0.82	0.13	0.77	0.51	0.73	0.82	0.3	0.48	0.97	-0.02	0.35	0.25	0.27	-0.14	0.88	0.82	0.35	0.88	0.26	0.72	0.49	0.65	0.49	0.2

Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	79.7B	80.4B	79.1B	60.1B	59.0B	32.8B
Short Long Term Debt Total	30.5B	27.2B	24.2B	21.0B	18.0B	11.0B
Other Current Liab	755M	13.5B	15.0B	14.5B	13.8B	14.5B
Total Current Liabilities	24.1B	22.1B	23.7B	22.8B	21.1B	11.2B
Total Stockholder Equity	12.0B	14.6B	15.1B	10.6B	13.3B	14.0B
Property Plant And Equipment Net	11.3B	11.0B	10.7B	9.6B	10.0B	7.2B
Net Debt	25.8B	20.9B	19.9B	17.3B	15.1B	8.3B
Accounts Payable	14.9B	4.4B	4.5B	3.9B	3.7B	5.1B
Cash	4.7B	6.3B	4.3B	3.7B	2.9B	2.7B
Non Current Assets Total	60.2B	60.2B	60.4B	39.4B	40.4B	20.9B
Non Currrent Assets Other	1.2B	1.1B	1.8B	5.3B	8.1B	8.5B
Cash And Short Term Investments	4.8B	6.4B	4.3B	7.9B	5.7B	4.0B
Common Stock Shares Outstanding	4.0B	2.0B	1.6B	2.0B	4.1B	4.3B
Liabilities And Stockholders Equity	79.7B	80.4B	79.1B	60.1B	59.0B	32.8B
Non Current Liabilities Total	37.3B	37.5B	34.1B	27.2B	25.1B	14.3B
Inventory	5.9B	6.0B	5.8B	5.1B	5.5B	3.0B
Other Stockholder Equity	4.9B	3.3B	3.3B	3.4B	3.5B	2.8B
Total Liab	61.3B	59.6B	57.8B	50.1B	46.2B	25.5B
Property Plant And Equipment Gross	10.3B	11.0B	10.7B	9.6B	20.2B	21.2B
Total Current Assets	19.5B	20.2B	18.7B	20.8B	18.6B	11.9B
Capital Stock	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Short Term Debt	6.9B	3.7B	3.6B	4.0B	2.8B	2.2B
Common Stock	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Retained Earnings	5.1B	6.8B	7.9B	4.4B	7.7B	8.1B
Accumulated Other Comprehensive Income	641M	1.6B	642M	(48M)	805M	845.3M
Intangible Assets	31.0B	29.8B	30.1B	14.3B	14.8B	11.4B
Other Liab	13.7B	14.1B	13.5B	10.2B	11.7B	14.2B
Long Term Debt	22.6B	23.4B	20.6B	17.0B	14.2B	17.5B
Good Will	10.6B	10.6B	10.6B	7.0B	6.8B	5.3B
Other Current Assets	1.6B	1.9B	1.7B	1.4B	1.6B	1.5B
Property Plant Equipment	11.3B	11.0B	10.7B	9.6B	8.7B	9.7B
Current Deferred Revenue	1.4B	1.8B	1.6B	299M	222M	233.1M
Other Assets	5.1B	5.3B	6.9B	6.9B	7.9B	5.4B
Net Receivables	7.1B	5.5B	6.2B	5.5B	5.9B	6.1B
Net Tangible Assets	(30.1B)	(25.8B)	(25.6B)	(10.8B)	(12.4B)	(13.0B)
Short Long Term Debt	6.7B	3.5B	3.4B	3.8B	2.7B	4.3B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:

How To Invest In GlaxoSmithKline

Details

Is GlaxoSmithKline Stock a good investment?

Details

What is GlaxoSmithKline PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.28)

Dividend Share

0.61

Earnings Share

1.53

Revenue Per Share

15.38

Quarterly Revenue Growth

(0.02)

The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlaxoSmithKline Ebit vs Research Development Analysis

Ebit vs Research Development

Ebit vs Research Development Correlation Analysis

Correlation Coefficient

Ebit

Research Development

GlaxoSmithKline PLC fundamental ratios Correlations

GlaxoSmithKline PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlaxoSmithKline PLC fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Capital Stock
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Inventory
Total Liab	+ 0.97	Total Assets
Inventory	+ 0.97	Property Plant And Equipment Net

Retained Earnings	- 0.71	Accounts Payable
Retained Earnings	- 0.66	Other Stockholder Equity
Accounts Payable	- 0.62	Other Current Liab
Common Stock Total Equity	- 0.61	Accounts Payable
Other Stockholder Equity	- 0.52	Common Stock Total Equity
Accounts Payable	- 0.44	Total Stockholder Equity